Original researchRosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: A 24-week, multicenter, randomized, double-blind, parallel-group study
References (54)
Pharmacologic therapy for type 2 diabetes mellitus
Ann Intern Med
(1999)- et al.
Real world effectiveness of rosiglitazone added to maxi mal (tolerated) doses of metformin and a sulfonylurea agent: A systematic evaluation oftriple oral therapy in a minority population
Diabetes Care
(2004) - et al.
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes (RECORD): A long-term cardiovascular outcome study
Diabetes
(2002) - et al.
Cardiovascular diseases and diabetes
- et al.
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
BMJ
(2000) Standards of medical care in diabetes
Diabetes Care
(2004)Medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management—2002 update
Endocr Pract
(2002)A desktop guide to type 2 diabetes mellitus
Diabet Med
(1999)Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada
Can J Diabetes
(2003)Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada
Can J Diabetes
(2003)Guidelines for the diagnosis, control and treatment of type 2 diabetes mellitus
Revista De La Asociacion Latinoamericana De Diabetes
(2000)
Type 2 Diabetes: Practical Targets and Treatments
Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes
JAMA
Evaluation of risk factors for develop ment of complications in type II diabetes in Europe
Diabetologia
Effect of intensive blood-glucose control with met formin on complications in overweight patients with type 2 diabetes (UKPDS 34)
Lancet
UK Prospective Diabetes Study 16. Overview of 6 years' ther apy of type II diabetes: A progressive disease
Diabetes
Need for intensive, early glycaemic control in patients with type 2 diabetes
Br j Cardiol
The burden of treatment failure in type 2 diabetes
Diabetes Care
Drug therapy: Metformin
N Engl J Med
Efficacy of metformin in pa tients with non-insulin-dependentdiabetes mellitus
N Engl J Med
Efficacy of metformin in type II diabetes: Results of a double blind, placebo-controlled, closeresponse trial
Am J Med
The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in pa tients with type II diabetes
Diabetes Care
The effects of metformin on cardiovascular risk factors
Diabetes Metab Rev
Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus
Aust N Z J Med
Is the cardioprotective effect of metformin in type 2 diabetes dose dependent?
Diabetes
Rosiglitazone monotherapy is effective in patients with type 2 diabetes
J Clin Endocrinol Metab
A comparison of the effects of rosiglitazone and gly buride on cardiovascular function and glycemic control in patients with type 2 diabetes
Diabetes Care
Effect of rosiglitazone treatment on nontraditional mark ers of cardiovascular disease in patients with type 2 diabetes mellitus
Circulation
Cited by (67)
A Systematic Review of Patient-Reported Satisfaction with Oral Medication Therapy in Patients with Type 2 Diabetes
2018, Value in HealthCitation Excerpt :Nevertheless, the only instrument designed for patients on oral therapy was the DTSQ. The DTSQs has been shown to be responsive when average initial satisfaction scores are less than 30 [38,41–43], yet when respondents are more satisfied with their current therapy at baseline, the DTSQs is not able to differentiate patient satisfaction, even if patients in the treatment group achieve significantly better glycemic control [44–48]. It is challenging to measure satisfaction with medication in a clinically meaningful way with the limited data currently available.
Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review
2017, Current Therapeutic Research - Clinical and ExperimentalThe role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact
2011, Trends in Pharmacological SciencesCitation Excerpt :Thus, combination therapy with metformin and TZDs could yield additive effects on hepatic and peripheral glucose metabolism. Table 2 summarizes the effects of adding TZD to metformin therapy in T2DM and clearly shows further lowering of FPG and peripheral insulin resistance [98–103]. There is also evidence that combined metfomin–TZD regimens are superior to the effect of adding sulfonylurea drugs to metformin therapy [104,105].
Adherence to Oral Antidiabetic Agents with Pioglitazone and Metformin: Comparison of Fixed-Dose Combination Therapy with Monotherapy and Loose-Dose Combination Therapy
2011, Clinical TherapeuticsCitation Excerpt :Monotherapy (MT) with oral antidiabetic agents (OADs) is the first-line pharmacologic treatment option(s); however, patients with more severe diabetes are managed with dual therapy. 9,10 Glycemic control has been shown to improve not only with dual therapy (compared with MT),11–15 but also with fixed-dose combination therapy (FDCT) (compared with loose-dose combination therapy [LDCT]).16,17 Although use of 2 agents may achieve better glycemic control, studies have shown that medication adherence typically decreases with the addition of another agent.18,19
Can the Mediterranean diet lower HbA1c in type 2 diabetes? Results from a randomized cross-over study
2011, Nutrition, Metabolism and Cardiovascular DiseasesCitation Excerpt :However, this current study is one of the few studies to examine the impact of a traditional Mediterranean-type diet (in a randomized cross-over trial), in its entirety, where the majority of foods (>70%) are provided to subjects, on weight and metabolic control of type 2 diabetes. The intervention resulted in a statistically and clinically significant improvement in glycemic control, equivalent to mono drug therapy [20–22]. Adherence to the prescribed diet was good, as indicated by changes in plasma biomarkers (MUFA, lutein and lycopene).
Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes
2011, Diabetes Research and Clinical Practice